Annovis Bio (ANVS) Income from Continuing Operations (2019 - 2026)
Annovis Bio (ANVS) posted Income from Continuing Operations of 18117200.0 for Q1 2026, down 75.63% sequentially from 10315412.0 in Q4 2025, and down 196.4% YoY from 18793514.5 in Q1 2025.
Annovis Bio (ANVS) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Annovis Bio has reported Income from Continuing Operations for 8 years, with the latest figure at 18117200.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 196.4% year-over-year to 18117200.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 42314328.0 (down 33.56% YoY) and the FY2025 annual result came in at 29773197.0, down 7.62% from the prior year.
- Income from Continuing Operations retreated to 18117200.0 in Q1 2026 per ANVS's latest filing, from 10315412.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1066947.0 in Q1 2024 and troughed at 22213394.0 in Q4 2023.
- A 5-year average of 9211587.24 and a median of 7726167.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 89.04% in 2024, then slumped 472.89% in 2025.
- Over 5 years, Income from Continuing Operations stood at 7726167.0 in 2022, then tumbled by 187.51% to 22213394.0 in 2023, then soared by 64.38% to 7911671.0 in 2024, then tumbled by 30.38% to 10315412.0 in 2025, then tumbled by 75.63% to 18117200.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 18117200.0, 10315412.0, and 7527658.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Annovis Bio | 67.91 Mn | 67.91 Mn | - | -14.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.12 Mn |
| Dec 31, 2025 | -10.32 Mn |
| Sep 30, 2025 | -7.53 Mn |
| Jun 30, 2025 | -6.35 Mn |
| Mar 31, 2025 | -6.11 Mn |
| Dec 31, 2024 | -7.91 Mn |
| Sep 30, 2024 | -12.64 Mn |
| Jun 30, 2024 | -5.02 Mn |
| Mar 31, 2024 | -1.07 Mn |
| Dec 31, 2023 | -22.21 Mn |
| Sep 30, 2023 | -14.72 Mn |
| Jun 30, 2023 | -9.54 Mn |
| Mar 31, 2023 | -9.74 Mn |
| Dec 31, 2022 | -7.73 Mn |
| Sep 30, 2022 | -6.43 Mn |
| Jun 30, 2022 | -5.94 Mn |
| Mar 31, 2022 | -5.23 Mn |
| Dec 31, 2021 | -5.91 Mn |
| Sep 30, 2021 | -2.85 Mn |
| Jun 30, 2021 | -2.52 Mn |